Find, compare & contact
Cantuzumab mertansine
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Cantuzumab mertansine API 400010-39-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Cantuzumab mertansine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Cantuzumab mertansine
- Synonyms:
- Immunoglobulin g1, anti-(mucin canag) (human-mouse monoclonal c242 heavy chain), disulfide with human-mouse monoclonal c242 light chain, dimer, compound with n(sup 2')-deacetyl-n(sup 2')-(3-mercapto-1-oxopropyl)maytansine (1:4) , Immunoglobulin g1, anti-(mucin canag) (human-mouse monoclonal c242 heavy chain), disulphide with human-mouse monoclonal c242 light chain, dimer, compound with n(sup 2')-deacetyl-n(sup 2')-(3-mercapto-1-oxopropyl)maytansine (1:4) , Immunoglobulin g1, anti-(mucin canag) human-mouse monoclonal c242 heavy chain), disulfide with human-mouse monoclonal c242 light chain, dimer, compound with n(sup 2')-deacetyl-n(sup 2')-(3-sulfanylpropanoyl)maytansine , Immunoglobulin g1, anti-(mucin canag) human-mouse monoclonal c242 heavy chain), disulphide with human-mouse monoclonal c242 light chain, dimer, compound with n(sup 2')-deacetyl-n(sup 2')-(3-sulphanylpropanoyl)maytansine , Maytansine, n2-deacetyl-n2-(3-mercapto-1-oxopropyl)-, conjugated humanized c242 monoclonal antibody , N2'-deacetyl-n2'-(3-mercapto-1-oxopropyl)-maytansine -conjugated humanized c242 monoclonal antibody
- Cas Number:
- 400010-39-1
- DrugBank number:
- DB17239
- Unique Ingredient Identifier:
- 7Z7EUX7R6M
General Description:
Cantuzumab mertansine is a chemical compound identified by the CAS number 400010-39-1. It is known for its distinct pharmacological properties and applications.
Classification:
Cantuzumab mertansine belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Categories:
Cantuzumab mertansine is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Antibodies, Antibodies, Monoclonal, Antibody-drug Conjugates, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Agents, Phytogenic, Blood Proteins, Globulins, Immunoconjugates, Immunoglobulins, Immunologic Factors, Immunoproteins, Immunotoxins, Lactams, Macrocyclic, Lactones, Macrolides, Noxae, Proteins, Serum Globulins, Toxic Actions. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Cantuzumab mertansine is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
